Literature DB >> 2791214

Dual inhibitory effect of bredinin.

T Kusumi1, M Tsuda, T Katsunuma, M Yamamura.   

Abstract

Bredinin inhibition of cell growth was investigated in the mouse lymphoma cell line L5178Y. Bredinin caused the accumulation of IMP and the reduction of XMP. It was converted to the 5'-phosphate within the cells. Bredinin 5'-phosphate but not bredinin competitively inhibited both IMP dehydrogenase and GMP synthetase. Thus the inhibition of cell growth is probably due to bredinin 5'-phosphate, which inhibits the consecutive enzyme reactions IMP dehydrogenase and GMP synthetase. These inhibitions result in the accumulation of IMP and the reduction of XMP.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2791214     DOI： 10.1002/cbf.290070308

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN： 0263-6484            Impact factor:   3.685


  12 in total

1.  Mizoribine-induced severe hyperglycemia in a patient with microscopic polyangiitis.

Authors:  Ryo Ishida; Kazumi Komaki; Tsuneyuki Nakanouchi; Tetsuro Kusaba
Journal:  CEN Case Rep       Date:  2013-09-26

2.  Study of the efficacy of mizoribine in lupus nephritis in Chinese patients.

Authors:  Miao Zhang; Chang Ying Xing; Jia Liu
Journal:  Rheumatol Int       Date:  2013-06-25       Impact factor: 2.631

3.  Usefulness of mizoribine administration in children with frequently relapsing nephrotic syndrome, and the relationship between pharmacokinetic parameters and efficacy: a multicenter prospective cohort study in China.

Authors:  Zheng-Kun Xia; Yuan-Fu Gao; Li-Ping Rong; Xi-Qiang Dang; Qian Shen; Xiao-Yun Jiang; Zhu-Wen Yi; Hong Xu
Journal:  World J Pediatr       Date:  2019-03-12       Impact factor: 2.764

4.  Inhibition of guanosine monophosphate synthetase by the substrate enantiomer L-XMP.

Authors:  Nicholas B Struntz; Tianshun Hu; Brian R White; Margaret E Olson; Daniel A Harki
Journal:  Chembiochem       Date:  2012-10-23       Impact factor: 3.164

5.  Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.

Authors:  Norishige Yoshikawa; Koichi Nakanishi; Kenji Ishikura; Hiroshi Hataya; Kazumoto Iijima; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2008-01-26       Impact factor: 3.714

6.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

7.  A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study.

Authors:  Tian-Zhong Yan; Xiao-Qiang Wu; Lu Rong
Journal:  SAGE Open Med       Date:  2016-05-11

8.  Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome.

Authors:  Takao Saito; Masayuki Iwano; Koichi Matsumoto; Tetsuya Mitarai; Hitoshi Yokoyama; Noriaki Yorioka; Shinichi Nishi; Ashio Yoshimura; Hiroshi Sato; Satoru Ogahara; Yoshie Sasatomi; Yasufumi Kataoka; Shiro Ueda; Akio Koyama; Shoichi Maruyama; Masaomi Nangaku; Enyu Imai; Seiichi Matsuo; Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2016-10-25       Impact factor: 2.801

Review 9.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13

10.  Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.

Authors:  Teruo Murakami; Nobuhiro Mori
Journal:  Pharmaceuticals (Basel)       Date:  2012-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.